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cation according to ‘worrisome features’ and ‘high-risk 
stigmata’. Recent prospective cohort studies evaluated 
whether these can be applied in clinical practice. Evalua-
tion of three different clinical scenarios with regard to 
costs and quality-adjusted life years suggested a better 
effectiveness of surveillance after initial risk stratification 
by endoscopic ultrasound-guided fine-needle aspiration 
with cyst fluid analysis compared with immediate resec-
tion or follow-up without further intervention. Of inter-
est, the ‘immediate surgery’ strategy was lowest for 
cost-effectiveness. Conclusions: The increasing inci-
dence of identified pancreatic cysts requires an im-
proved strategy for non-invasive risk stratification based 
on advanced imaging strategies. In light of a malignancy 
risk of 2% for branch-duct IPMN, the socio-economic ne-
cessity of a balance between surveillance and resection 
has to be agreed on.
Introduction
The increasing sensitivity of imaging modalities gave rise to an 
increase of pancreatic cystic lesions (PCL) since the mid-nineties. 
In parallel, an increased number of resected intraductal papillary 
mucinous neoplasm (IPMN) was reported [1]. Autopsy series de-
tected small pancreatic cysts in a range of 24.3–27.5% and hereby 
determined the prevalence [2, 3]. Only in a minority of cases the 
pathologist regarded these lesions as harboring a potential risk of 
malignancy (3%). In the context of epidemiological studies and in 
cross-sectional imaging for other indications, the number of PCL 
increased to 2.6% on computed tomography scans (CT) and to 
27.7% in secretin-enhanced magnetic resonance imaging (MRI) 
studies [4–6], suggesting that MRI is now as sensitive as autopsy 
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Summary
Background: Increased usage of computed tomography 
and magnetic resonance imaging has led to a large in-
crease in identified pancreatic cysts of up to 25% in pop-
ulation-based studies. The clinical and economic rele-
vance of identifying so many cystic lesions has not been 
established. Compared to other organs such as liver or 
kidney, dysontogenetic pancreatic cysts are rare. Pancre-
atic cysts comprise a variety of benign, premalignant or 
malignant lesions; however, precise diagnosis before re-
section has an accuracy of only 80%. The focus of recent 
research was the malignant potential of intraductal pap-
illary mucinous neoplasms (IPMN) with the aim of estab-
lishing clinical pathways addressing risk of malignancy, 
age and comorbidity, treatment-related morbidity and 
mortality as well as cost-effectiveness of treatment and 
surveillance. The focus of this review is to analyze the 
clinical and socio-economic relevance as well as the 
cost-benefit relation for IPMNs. Methods: For analysis, 
the following MESH terms were used to identify original 
articles, reviews, and guidelines in PubMed: (‘intraductal 
papillary mucinous neoplasm’ OR ‘pancreatic cysts’) and 
(incidence OR relevance OR socio-economic OR eco-
nomic OR cost-effectiveness OR cost-benefit). The re-
trieved publications were reviewed with a focus on clini-
cal and socio-economic relevance in relation to the in-
creasing incidence of IPMN. Results: Addressing the in-
creasing prevalence of pancreatic cystic lesions, recent 
consensus guidelines suggested criteria for risk stratifi-
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studies. In the Rochester Epidemiology Project, a 14-fold increase 
in the incidence rate of IPMNs between 1985 and 2005 was ob-
served (0.31–4.35 cases per 100,000 persons) [7] which was most 
likely caused by two effects: the improvement in detection rate as 
well as the aging population. The aging population contributes to 
the higher prevalence of PCL as well as to mucin-producing adeno-
carcinoma in patients with pancreatic cysts at a rate of 33.2 per 
100,000 (95% confidence interval (CI): 21.6–44.0) [8]. There is a 
linear increase in the rate of malignant transformation with in-
creasing age up to 38.6 per 100,000 in 80- to 84-year-old men. In 
the absence of a PCL, the prevalence of mucin-producing adeno-
carcinomas in US adults between 40 and 84 years of age was 0.83 
per 100,000. Of note, the mortality rate for pancreatic adenocarci-
noma and IPMN-associated pancreatic adenocarcinoma did not 
increase over the same time period, suggesting a stable number of 
PCL now detected by improved imaging modalities rather than a 
net increase in incidence [9, 10]. IPMN-associated carcinoma in-
creased from 0.008 to 0.032 per 100,000 persons in 2001 to 0.06 per 
100,000 persons in 2007. Because overall pancreatic cancer mortal-
ity remained stable between 1975 and 2007, the effect is again 
caused by a better detection of the IPMN association of pancreatic 
cancer. Thus, the increased detection of IPMN had no impact on 
pancreatic cancer-related mortality. These observations suggest 
that unfortunately most PCL including IPMNs are of no overall 
clinical relevance since mortality is considered the most relevant 
outcome or study endpoint. Nevertheless, the increased detection 
of PCL in the recent past triggered extensive diagnostic investiga-
tions to clarify the potential risk of malignancy as well as the conse-
quences of surgical resection which does not benefit all patients. 
Methods
A literature search was undertaken in PubMed for original 
 publications, reviews, and guidelines with the following keywords 
(‘intraductal papillary mucinous neoplasm’ OR ‘pancreatic cysts’) 
and (incidence OR relevance OR socio-economic OR economic 
OR cost-effectiveness OR cost-benefit). The retrieved publications 
were reviewed with a focus on clinical and socio-economic out-
comes as well as on the increasing incidence and detection of 
IPMN.
IPMN Subtypes
IPMNs are characterized by an intraductal proliferation of epi-
thelia combined with the production and secretion of mucus. De-
pending on the localization of the IPMN, they are divided into 
main-duct IPMN (MD-IPMN), branch-duct IPMN (BD-IPMN), 
and mixed-type IPMN [11, 12]. The majority of IPMNs are BD-
IPMNs and occur at a single site. In 20–30%, they present as multi-
focal lesions, and in 5–10% they can be found spread over the en-
tire pancreas in a field defect [4, 13]. Considering the localization 
of the lesion, the potential of malignancy varies between 57–92% in 
MD-IPMN and 6–42% in BD-IPMN [14]. There is almost general 
agreement that the diagnosis of MD-IPMN requires resection and 
that this strategy is cost-effective. In the case of a mixed-type 
IPMN, the main duct lesion determines the prognosis.
In the largest prospective cohort study, BD-IPMNs were diag-
nosed as an incidental finding in 57%, with a predominance in the 
7th decade of life. The risk of progression was below 5%, and the 
risk of invasive growth during the surveillance period was below 
2% [15]. In contrast, the operative mortality ranged between 1.3 
and 8%, highlighting the necessity of accurate preoperative diag-
nosis. Besides imaging criteria such as size or mural nodules, BD- 
IPMNs can be classified into different histological subtypes. These 
include an intestinal, a pancreatobiliary, an oncocytic, and a gastric 
cellular subtype. The first three mainly present as MD-IPMNs and 
are localized in the pancreatic head and body. The pancreatobiliary 
subtype is burdened with the worst outcome due to its high proba-
bility of the development of pancreatic adenocarcinoma [16, 17]. 
The gastric subtype is often identified in BD-IPMNs and harbors a 
lower risk of malignancy with a longer time interval of progression 
to pancreatic adenocarcinoma. However, those histological sub-
classifications are not considered for risk stratification, because 
they cannot be determined prior to resection.
The aim of the IPMN guidelines from 2006 [14] and 2012 [18] 
was to establish criteria predicting invasive IPMN or IPMN with 
high-grade dysplasia. With the help of extended criteria named 
‘high-risk stigmata’ (obstructive jaundice in a patient with cystic 
lesion of the head of the pancreas, enhancing solid components 
within a cyst, main pancreatic duct >10 mm in size) and ‘worri-
some features’ (clinical pancreatitis, imaging: cyst >3 cm, thick-
ened/enhancing cyst walls, main duct size 5–9 mm, non-enhancing 
mural nodule, abrupt change in caliber of pancreatic duct with dis-
tal pancreatic atrophy), a better discrimination was achieved. In a 
retrospective analysis of 100 resected patients with IPMN, the 
number of high-risk stigmata correlated well with the grade of ma-
lignancy of BD-IPMNs and therefore independently validated the 
consensus criteria [19].
Clinical Value of the Consensus Guidelines
Fernandez-Castillo and co-workers have used the revised inter-
national consensus guideline [18] in a prospective database includ-
ing 762 patients with BD-IPMN [20]. In this cohort and in adher-
ence to the guideline, 20% of the patients underwent surgical resec-
tion at the time of diagnosis. An additional 21% of the patients 
were resected during the 5-year surveillance period. In summary, 
high-grade dysplasia or invasive cancer was associated with an age 
above 65 years, a cyst size of more than 3 cm (56.3 vs. 38.5%; p = 
0.028), main duct dilation or stricture, as well as multifocal disease 
(52.4 vs. 31.1%; p = 0.049). Jaundice, mural nodules or masses, and 
an increase of serum carbohydrate antigen (CA) 19-9 over 37 kU/l 
were associated with invasive cancer (26 vs. 13%; p = 0.031). CA 
19-9 was elevated in 89% of all resected patients, in only 35% of re-
sected patients with invasive BD-IPMN, but only in 14% of pa-
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tients with benign lesions. Ultimately, CA 19-9 was unable to dis-
criminate between invasive or non-invasive IPMN [20–22]. 
Among all resected patients, invasive cancer was present in only 
10% and high-grade dysplasia in a further 14%, suggesting that 
76% of the patients underwent surgery in vain. When a cyst size 
smaller than 3 cm was taken into account, high-grade dysplasia 
and invasive cancer were found in 10 and 7%. No cancer was diag-
nosed in cysts smaller than 2 cm. No dysplasia was found in lesions 
smaller than 1 cm. In 27.6% of all IPMNs, worrisome features were 
detected and those underwent surgery in nearly all cases (97%). In 
only 29% of them, however, high-grade dysplasia or invasive can-
cer was detected on resection specimen. Therefore, in retrospect, 
more than 70% of resected patients underwent surgery without po-
tential benefit. In contrast, in the absence of worrisome features 
and thus Sendai/Fukuoka criteria-negative BD-IPMN (guidelines 
from 2012 [18]), the rate of invasive cancer was 0.26% (1 in 500) 
and high-grade dysplasia was found in 9%. Worrisome features 
were significantly more common in patients with histologically 
 diagnosed high-grade dysplasia or invasive carcinoma (85 vs. 59%, 
p = 0.001) in comparison to those with low-grade or moderate dys-
plasia. Of note, no patient developed pancreatic cancer during sur-
veillance. Median survival in resected invasive carcinoma arising 
from BD-IPMN was 110 months (95% CI: 5–214 months; 2-year 
survival: 84%) compared to 13 months for patients with BD-IPMN 
and concurrent pancreatic ductal adenocarcinoma (95% CI: 5–21 
months; 2-year survival: 23%). The data outlined here in detail 
 reflect findings from all prospective studies so far reported and 
 include 1,502 patients [20–28]. 
Cost-Effectiveness Analysis
The data above demonstrate the applicability and clinical rele-
vance of the revised consensus criteria for the follow-up of IPMNs 
[18]. The remaining question is whether this strategy is cost-effec-
tive. The above data also clarify approaches that the sensitivity for 
the detection of malignancy according to the consensus guidelines 
is 100%, but the specificity is only 23–31%, resulting in a high 
number of false-positive findings and unnecessary surgery [29, 30]. 
Given the direct and indirect cost incurred by surgical resection, 
the strategy might not be cost-effective. A recent study focused on 
the cost-effectiveness of the 2006 consensus guidelines in the man-
agement of BD-IPMN, comparing surveillance to no surveillance 
and immediate surgery [31]. The hypothetical cohort recruited 
60-year-old patients with BD-IPMN in the head of the pancreas. 
Three strategies were generated: The first included surveillance 
following the consensus guidelines from 2006 and establishing a 
surveillance strategy with possible surgical resection whenever in-
dicated. The second strategy was based on intervention only in the 
case of symptoms without surveillance (no surveillance strategy). 
The third model calculated the effect of immediate surgery in all 
cases (surgery strategy). Employing the model of Markov, a life-
time horizon was evaluated. The results indicated that the no sur-
veillance strategy was the least effective with regard to quality-ad-
justed life years (QALY) gained but the cheapest. The surveillance 
strategy was more effective in terms of survival but more costly. In 
this study, the most costly but most effective strategy with regard to 
QALY gained was immediate surgery, in which only 5.4% died 
from invasive cancer whereas 4.7% died as a consequence of sur-
gery. Of note, 1 in 20 patients died from surgical complications. In 
the surveillance strategy, 9.7% died from cancer and 4.5% follow-
ing surgery in comparison to the no surveillance strategy where 
11.2 and 4.4% died from cancer or surgery, respectively. Since the 
number of patients undergoing surgery was, of course, very differ-
ent between the groups, the surveillance strategy had the lowest 
risk of death. Although the surgery strategy had the highest QALY 
gained, it was associated with the highest cost of up to USD 132,436 
per QALY in comparison to the surveillance strategy. Depending 
on the health care setting, a QALY of USD 25,000–50,000 is ac-
cepted by society. Immediate surgery in the setting of IPMN would 
exceed this amount by far. The USD 50,000/QALY was used as a 
benchmark for hemodialysis. In summary, employing the surveil-
lance strategy suggested by the consensus guidelines would result 
in 88.1% of patients being covered by the set benchmark of USD 
50,000/QALY (fig.  1). The reason why immediate surgery is not 
cost-effective is due to the low specificity of 23–30% achieved by 
Fig. 1. Acceptability curve of no surveillance ver-
sus surveillance strategies. Based on willingness- 
to-pay (WTP) threshold (USD per QALY) on the 
horizontal axis. The axis represents the proportion 
of simulated trials in the Monte Carlo probabilistic 
sensitivity analysis that would fall within a speci-
fied budget. For example, a USD 50,000 WTP 
threshold results in 88.1% cost-effectiveness pro-
portion in the simulated trials if a surveillance 
strategy would be pursued. In addition, the net 
health benefit is positive at a WTP threshold of 
USD 20,291 for the surveillance strategy (modified 
from [30]).
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preoperative diagnostic measures, which lead to false-positive di-
agnosis with 70–77% of patients undergoing unnecessary surgery. 
Based on a careful consideration of the cost per life year saved, em-
ploying the surveillance strategy suggested by the consensus guide-
lines indicates that it is in the cost range of colorectal cancer 
screening programs [32, 33]. Moreover, as direct mortality and 
morbidity of pancreatic surgery should not be disregarded, the sur-
veillance strategy should be preferred because it allows for a higher 
sensitivity to diagnose malignancy at lower costs. A caveat should 
be mentioned in this context: At the age of 78 years, the cost for 
one QALY rises above USD 50,000 and the no surveillance strategy 
is more cost-effective. In this situation, comorbidity drives out-
come. 
A second study used a similar approach to analyze cost-effec-
tiveness following the release of the consensus guidelines in 2006 
[34]. In this analysis, which also employed a Markov model, the 
clinical course of the patients were adjusted for age, sex, and mor-
tality with regard to individual health and disease states including 
cancer-related mortality [35]. Again the authors created three dif-
ferent scenarios: The first (strategy I) recruited patients with prob-
able serous cystic neoplasms on cross-sectional imaging. These 
were followed as a benign disease using a ‘watch and wait’ strategy. 
In the second group (strategy II), all patients were resected if they 
were fit for surgery. The patients did not undergo further surveil-
lance after surgery. The third group (strategy III) underwent pre-
operative endoscopic ultrasound (EUS) with fine-needle aspiration 
(FNA) and cyst fluid analysis. Depending on the individual surgi-
cal risk and the result of the FNA (mucinous vs. serous cystic le-
sion), patients underwent surgical resection. EUS with FNA and 
fluid analysis distinguish between mucinous and non-mucinous 
cysts [36]. EUS was also used to identify high-risk stigmata and 
worrisome features in order to increase the diagnostic accuracy. 
The standard patient was 65 years of age with a 3-cm incidental 
cystic lesion in the tail of the pancreas and an ASA (American Soci-
ety of Anesthesiologists) score of III. The analysis revealed that 
strategy II is the cheapest (USD 13,200 per patient) but gains the 
lowest QALY (9.66). Strategy I resulted in a QALY of 10.34 at 
slightly higher costs (USD 18,883 per patient). Strategy III was bur-
dened with the highest costs (USD 23,337 per patient) but also the 
highest QALY (10.73). Finally, the ICER (incremental cost-effec-
tiveness ratio) of group III was only USD 11,394 and that of group 
II amounted to USD 9,474, emphasizing that the additional costs 
were well invested and remained in an acceptable range. 
For the allocation of an optimal management strategy, the most 
important factor remains the risk of surgery. In a group with a low 
risk for developing malignancy or a higher risk for operative com-
plications, resection was never the best strategy regardless of the 
model used. The discrimination between a serous and a mucinous 
lesion is important to determine a cost-effective strategy. If the pre-
operative diagnosis falls short in the discrimination between be-
nign and premalignant lesion and the probability drops to less than 
27%, EUS-FNA stratification (strategy III) is no longer cost-effec-
tive. If the preoperative accuracy for a benign cyst is higher than 
77%, then a ‘watch and wait’ strategy becomes the most cost-effec-
tive (fig. 2). It is therefore important that each institution involved 
in the surveillance and treatment of IPMNs is aware of the diag-
nostic accuracy of its own institutional tools. As suggested by 
Huang et al. [30], in the case of older patients burdened with co-
morbidity (ASA II–III) as well as localization of the cysts in the 
pancreatic head, a ‘watch and wait’ strategy should be preferred 
from a cost-effectiveness standpoint. Nevertheless, in a Monte 
Carlo analysis, there is a higher risk for this group to develop un-
resectable pancreatic cancer if compared to the FNA strategy. 
Whether that is of clinical relevance needs to be decided by the 
multidisciplinary team involved in the treatment and is based on 
risk assessment and risk stratification. Finally, initial EUS with 
FNA and cyst fluid analysis was found to have the most beneficial 
effect with the highest QALY gained as well as ICER, but only if the 
mortality risk of surgery was at or below 4.7%.
In summary, in these analyses, surgical resection for all patients 
with an incidental solitary PCL was not the preferred option on 
the basis of cost-effectiveness. A preoperative diagnostic work-up 
by EUS with FNA and cyst fluid analysis should be employed to 
lower the rate of unnecessary surgery and to decrease surgical 
morbidity and mortality. Risk stratification is therefore mandatory 
and it should be kept in mind that the risk of a SB(side branch)-
IPMN progressing to invasive cancer is 2% per year and corre-
sponds to the risk of stroke associated with atrial fibrillation. We 
assess the risk of bleeding before we prescribe an anticoagulant in 
this situation and should likewise assess the risk in SB-IPMN be-
fore advising surgery. An individual strategy for each cyst and 
each patient is necessary in order to achieve optimal but cost-ef-
fective therapy.
Fig. 2. Result of a one-way sensitivity analysis with the X-axis showing the 
probability of a mucinous cystic lesion being benign at entry into the model and 
the Y-axis showing the corresponding ICER. Strategy III is consistently more 
cost-effective – except when the probability of a mucinous cystic lesion being 
benign exceeds 77%. In this case, strategy I (watch and wait) becomes more 
cost-effective (K = 1,000) (modified from [33]).
Clinical and Socio-Economic Relevance of IPMN Viszeralmedizin 2015;31:47–52 51
Conclusion
On the one hand, the widespread use of cross-sectional imaging 
during the last two decades revealed a rapidly increasing number of 
PCL harboring the potentially life-threatening risk of pancreatic 
cancer for the patient. On the other hand, the incidence rate of 
pancreatic malignancy has been stable over the same two decades. 
We have reached the point where advanced imaging modalities 
reach the sensitivity of autopsy studies and therefore the preva-
lence peak of PCL. However, preoperative diagnostic specificity 
and accuracy for classifying these cystic lesions remains poor. 
Therefore, the management of potentially premalignant lesions 
such as BD-IPMN remains challenging. A critical appraisal of the 
published literature suggests that the treatment outcome of what is 
presumed to be a BD-IPMN remains unsatisfactory, with a large 
rate of surgically overtreated patients. Until we have collated a 
more comprehensive understanding of the natural history of BD-
IPMNs, the management of patients with pancreatic cysts should 
be individually tailored and preferably carried out in centers with a 
high caseload. At present, the authors confirm that the Sendai con-
sensus guidelines revised in Fukuoka are not only clinically rele-
vant and applicable but also cost-effective and of sufficient concern 
regarding socio-economic factors. 
A cancer prevention strategy for PCL greatly differs from the 
management of other premalignant lesions in the gastrointestinal 
tract in two important ways. A snare polypectomy reduces the risk 
of developing colorectal cancer by 70% and has been shown to in-
crease overall survival; compared to respective pancreatic surgery, 
the procedural risk is minimal. Moreover, IPMNs are field defects 
of the pancreas and, as in the colon, they have a tendency, or they 
are multifocal in up to 30%, resulting in extended surgery with an 
even higher operative risk [37]. Lastly, BD-IPMNs are in 4% asso-
ciated with synchronous or metachronous pancreatic ductal ade-
nocarcinoma arising from the non-IPMN-affected pancreatic tis-
sue. Surgery of an IPMN therefore only reduces but does not abol-
ish the risk of developing pancreatic cancer in the remaining organ 
[38]. After surgery, lifelong surveillance is thus recommended, and 
a second operation, if it is not a total pancreatectomy, is challeng-
ing for both the patient and the surgeon. Careful consideration of 
probable complications is required as they involve significant mor-
bidity and mortality.
One aspect of enhancing diagnostic specificity is the identifica-
tion of the BD-IPMN subtypes by EUS-FNA [17, 39]. Ultimately it 
is our goal to increase the diagnostic accuracy for PCL to improve 
risk stratification and management, and to reduce health care ex-
penditure but still not to miss the 1 in 500 of the BD-IPMN pa-
tients who will have invasive cancer and who are burdened with 
the poorest prognosis of all gastrointestinal malignancies.
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